Roivant Sciences (NASDAQ:ROIV) Insider Sells $653,458.70 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 17,519 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $37.30, for a total transaction of $653,458.70. Following the completion of the transaction, the insider directly owned 18,630,739 shares in the company, valued at $694,926,564.70. The trade was a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88.
• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total transaction of $6,426,655.83.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $36.30 on Monday. Roivant Sciences Ltd. has a fifty-two week low of $11.60 and a fifty-two week high of $37.97. The company has a 50 day moving average price of $34.61 and a 200 day moving average price of $30.48. The stock has a market capitalization of $26.22 billion, a P/E ratio of -68.49 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Research analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP raised its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares in the last quarter. Parallel Advisors LLC lifted its stake in Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Roivant Sciences during the 4th quarter worth approximately $47,000. Finally, Bessemer Group Inc. grew its holdings in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ROIV shares. HC Wainwright boosted their price target on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research note on Thursday, August 6th. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Citigroup increased their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.